Sagebrush Inn & Suites Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2017
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
TGF-ß in Immunity, Inflammation and Cancer (A3)
Organizer(s) Wanjun Chen, Joanne E. Konkel and Richard A. Flavell
January 9—13, 2017
Sagebrush Inn & Suites • Taos, New Mexico USA
Discounted Abstract Deadline: Sep 20, 2016
Abstract Deadline: Oct 11, 2016
Scholarship Deadline: Sep 20, 2016
Discounted Registration Deadline: Nov 10, 2016
Sponsored by BioLegend, Inc., EMD Serono Research and Development Institute, Inc. and Regeneron Pharmaceuticals, Inc.
Summary of Meeting:
TGF-beta is a key regulator of immune responses, inflammation and cancer. In addition to the well-established effects of TGF-beta on CD4+ T cell differentiation and reprogramming, TGF-beta also plays critical roles in other immune cells. Furthermore, TGF-beta has been implicated in the regulation of the interactions among immune cells, microbiota and epithelial cells. In addition to safeguarding immune homeostasis and suppressing chronic inflammation and autoimmunity, TGF-beta is emerging as a potential checkpoint in anti-tumor immunity. Despite great progress in the field, key questions related to TGF-beta functions in immune responses are still largely undetermined. Therefore, it is imperative to understand the cellular and molecular mechanisms by which TGF-beta controls such diverse immune cells. Elucidation of these pathways would allow us to understand the pathogenesis of chronic inflammation, autoimmunity and cancer and aid development of therapeutic practices in experimental and ultimately clinical settings. This meeting will gather together experts in the fields of both TGF-beta signaling and immunology to discuss new findings and update the pivotal role of TGF-beta in immunity, inflammation and cancer, with the aim to lay out the critical and key questions and outline new directions.
View Scholarships/Awards
TGF-beta is a key regulator of immune responses, inflammation and cancer. In addition to the well-established effects of TGF-beta on CD4+ T cell differentiation and reprogramming, TGF-beta also plays critical roles in other immune cells. Furthermore, TGF-beta has been implicated in the regulation of the interactions among immune cells, microbiota and epithelial cells. In addition to safeguarding immune homeostasis and suppressing chronic inflammation and autoimmunity, TGF-beta is emerging as a potential checkpoint in anti-tumor immunity. Despite great progress in the field, key questions related to TGF-beta functions in immune responses are still largely undetermined. Therefore, it is imperative to understand the cellular and molecular mechanisms by which TGF-beta controls such diverse immune cells. Elucidation of these pathways would allow us to understand the pathogenesis of chronic inflammation, autoimmunity and cancer and aid development of therapeutic practices in experimental and ultimately clinical settings. This meeting will gather together experts in the fields of both TGF-beta signaling and immunology to discuss new findings and update the pivotal role of TGF-beta in immunity, inflammation and cancer, with the aim to lay out the critical and key questions and outline new directions.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Monday, January 9 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Friday, January 13 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Saturday, January 14 in order to fully experience the meeting.
MONDAY, JANUARY 9
TUESDAY, JANUARY 10
WEDNESDAY, JANUARY 11
THURSDAY, JANUARY 12
FRIDAY, JANUARY 13
SATURDAY, JANUARY 14
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Monday, January 9 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Friday, January 13 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Saturday, January 14 in order to fully experience the meeting.
MONDAY, JANUARY 9
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Wanjun Chen,
NIDCR, National Institutes of Health, USA
Rik Derynck,
University of California, San Francisco, USA
TGF-beta Responses and Control of TGF-beta Responsiveness
TGF-beta Responses and Control of TGF-beta Responsiveness
09:00—11:30
TGF-beta Superfamily: Basic Mechanisms of Signal Transduction
Meeting has ended...abstracts no longer viewable online.
*
Howard L. Weiner,
Brigham and Women’s Hospital, Harvard Medical School, USA
Joan Massagué,
Memorial Sloan Kettering Cancer Center, USA
Contextual Determinants of TGF-beta Signaling in Normal and Oncogenic Stem Cells
Contextual Determinants of TGF-beta Signaling in Normal and Oncogenic Stem Cells
Coffee Break
Stefan Karlsson,
Lund University, Sweden
TGF-beta Signaling in Hematopoietic Stem Cells
TGF-beta Signaling in Hematopoietic Stem Cells
Peter ten Dijke,
Leiden University Medical Center, Netherlands
TGF-beta Receptor Signal Transduction in Breast Cancer
TGF-beta Receptor Signal Transduction in Breast Cancer
Aristidis Moustakas,
Uppsala University, Sweden
Short Talk: Epigenetic Control and Micro-RNA Processing Connect TGFBeta to EMT and Tumor Cell Stemness
Short Talk: Epigenetic Control and Micro-RNA Processing Connect TGFBeta to EMT and Tumor Cell Stemness
Ying E. Zhang,
NCI, National Institutes of Health, USA
Short Talk: Direct Regulation of Alternative Splicing by SMAD3 is Essential to the Tumor-Promoting Role of TGF-beta
Short Talk: Direct Regulation of Alternative Splicing by SMAD3 is Essential to the Tumor-Promoting Role of TGF-beta
14:30—16:30
Workshop 1: TGF-ß in Fate Decisions and Cellular Functions
*
Akihiko Yoshimura,
Keio University, Japan
Amina Dahmani,
University of Montreal, Maisonneuve-Rosemont Hospital Research Center, Canada
Transforming Growth Factor-beta Programs Central-Memory Differentiation In Ex-Vivo Stimulated Human T Cells By Modulating Id3 Expression
Transforming Growth Factor-beta Programs Central-Memory Differentiation In Ex-Vivo Stimulated Human T Cells By Modulating Id3 Expression
Matthew Riese,
Medical College of Wisconsin, USA
PECAM-1, a TGF-beta Receptor Binding Protein, Contributes to CD8+ T Cell Exhaustion
PECAM-1, a TGF-beta Receptor Binding Protein, Contributes to CD8+ T Cell Exhaustion
Fernando Souza-Fonseca-Guimaraes,
Walter and Eliza Hall Institute, Australia
TGF-beta Inhibits NK Cell Activation and Cytotoxicity through Repression of the mTOR Pathway
TGF-beta Inhibits NK Cell Activation and Cytotoxicity through Repression of the mTOR Pathway
Hongbo Hu,
Sichuan University, China
Non-Canonical NF-kappaB: The Regulating Mechanism and Application in Cancer Immunology
Non-Canonical NF-kappaB: The Regulating Mechanism and Application in Cancer Immunology
Lopa Mishra,
George Washington University, USA
An Integrated Approach Towards Dissecting the Dichotomy of the TGF-beta Pathway in Liver Inflammation and Cancer: Insights from a Human Stem Cell Syndrome, TCGA Analyses, and Mouse Models
An Integrated Approach Towards Dissecting the Dichotomy of the TGF-beta Pathway in Liver Inflammation and Cancer: Insights from a Human Stem Cell Syndrome, TCGA Analyses, and Mouse Models
Claire Gustafson,
Stanford University, USA
Age-Related Changes in MicroRNA Expression Alter TGF-beta Signaling in Naïve CD8 T Cells during Human Immune Aging
Age-Related Changes in MicroRNA Expression Alter TGF-beta Signaling in Naïve CD8 T Cells during Human Immune Aging
Lily Huang,
Regeneron Pharmaceutical, USA
Inhibition of Activin A Stops the Regrowth of Surgically Resected Heterotopic Bone in a Mouse Model of Fibrodysplasia Ossificans Progressiva and Indicates a New Potential Path to Therapy
Inhibition of Activin A Stops the Regrowth of Surgically Resected Heterotopic Bone in a Mouse Model of Fibrodysplasia Ossificans Progressiva and Indicates a New Potential Path to Therapy
17:00—19:00
TGF-ß in Hematopoietic Stem Cells and Innate Immunity
Meeting has ended...abstracts no longer viewable online.
Ursula Grohmann,
University of Perugia, Italy
TGF-beta, Arg1, and IDO1: An Immunosuppressive Module at Work in Dendritic Cells
TGF-beta, Arg1, and IDO1: An Immunosuppressive Module at Work in Dendritic Cells
Herbert Strobl,
Medical University Graz, Austria
TGF-beta1 and BMP Signaling in Langerhans Cells
TGF-beta1 and BMP Signaling in Langerhans Cells
*
Richard A. Flavell,
HHMI/Yale University School of Medicine, USA
TGF-beta Controls Th17 Plasticity and Maintains Intestinal Homeostasis
TGF-beta Controls Th17 Plasticity and Maintains Intestinal Homeostasis
Sylvain Perruche,
Etablissement Français du Sang BFC, France
Short Talk: The Resolutive Factors Issued from Apoptotic Cell Clearance Allow the Termination of Ongoing Inflammation
Short Talk: The Resolutive Factors Issued from Apoptotic Cell Clearance Allow the Termination of Ongoing Inflammation
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
TGF-ß in T Cells I
Meeting has ended...abstracts no longer viewable online.
*
John J. O'Shea,
NIAMS, National Institutes of Health, USA
Vijay K. Kuchroo,
Brigham and Women's Hospital, Harvard Medical School, USA
TGF-beta Induces Dominant Regulators that Promote Unidirectional Development of Foxp3+ Treg
TGF-beta Induces Dominant Regulators that Promote Unidirectional Development of Foxp3+ Treg
Timothy A. Springer,
Immune Disease Institute, Harvard University, USA
A Microglia Context Molecule for TGF-beta Required for Maintenance of Nervous System Function
A Microglia Context Molecule for TGF-beta Required for Maintenance of Nervous System Function
Coffee Break
Akihiko Yoshimura,
Keio University, Japan
Induction of Stable TGF-ß-Mediated Regulatory T Cells by Epigenetic Modifications
Induction of Stable TGF-ß-Mediated Regulatory T Cells by Epigenetic Modifications
Yisong Wan,
University of North Carolina at Chapel Hill, USA
Short Talk: TGF-beta Signaling in Controlling Diverse T Cell Functions
Short Talk: TGF-beta Signaling in Controlling Diverse T Cell Functions
17:00—19:00
TGF-ß in T Cells II
Meeting has ended...abstracts no longer viewable online.
*
Vijay K. Kuchroo,
Brigham and Women's Hospital, Harvard Medical School, USA
John J. O'Shea,
NIAMS, National Institutes of Health, USA
TGF-ß and MicroRNA in T Cell Plasticity
TGF-ß and MicroRNA in T Cell Plasticity
Sophie Lucas,
de Duve Institute, Belgium
GARP-Dependent Activation of TGF-beta1 Mediates Immunosuppression by Human and Mouse Tregs
GARP-Dependent Activation of TGF-beta1 Mediates Immunosuppression by Human and Mouse Tregs
Chen Dong,
Tsinghua University, China
Smad2 and Smad4 in T Cells
Smad2 and Smad4 in T Cells
Zihai Li,
Medical University of South Carolina, USA
Short Talk: Cancer Promotion and Immune Tolerance Via A Novel gp96-GARP-TGF-beta Switch: Mechanisms and Opportunities
Short Talk: Cancer Promotion and Immune Tolerance Via A Novel gp96-GARP-TGF-beta Switch: Mechanisms and Opportunities
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
TGF-ß in Emerging Immune Cells
Meeting has ended...abstracts no longer viewable online.
*
Lucienne Chatenoud,
INSERM U1151, Hôpital Necker-Enfants Malades, France
Shannon J. Turley,
Genentech, Inc., USA
Regulation of Tumor Immunity by Stromal Cells
Regulation of Tumor Immunity by Stromal Cells
Yasmina Laouar,
University of Michigan, USA
TGF-beta in Innate Cells Matters
TGF-beta in Innate Cells Matters
Coffee Break
Joanne E. Konkel,
University of Manchester, UK
TGF-beta in Regulatory T Cell Function
TGF-beta in Regulatory T Cell Function
Julien C. Marie,
INSERM/Cancer Research Center of Lyon, France
TGF-beta Signaling in Peculiar Innate Cells
TGF-beta Signaling in Peculiar Innate Cells
Victor S. Cortez,
Washington University in St. Louis, USA
Short Talk: Transforming Growth Factor-beta and Eomes Conversely Guide the Differentiation of ILC1 and NK Cells
Short Talk: Transforming Growth Factor-beta and Eomes Conversely Guide the Differentiation of ILC1 and NK Cells
Yuanming Xu,
Northwestern University, USA
Short Talk: The E3 Ubiquitin Ligase Hrd1 Regulates TGF-beta Signaling Pathway to Maintain Regulatory T Cells Generation and Suppressive Function
Short Talk: The E3 Ubiquitin Ligase Hrd1 Regulates TGF-beta Signaling Pathway to Maintain Regulatory T Cells Generation and Suppressive Function
17:00—19:00
TGF-ß in Mucosal Immunity and in Immune Tolerance
Meeting has ended...abstracts no longer viewable online.
*
Chen Dong,
Tsinghua University, China
Howard L. Weiner,
Brigham and Women’s Hospital, Harvard Medical School, USA
LAP-TGF-beta Immune Cells in Mucosal Immunity, Tolerance and Cancer
LAP-TGF-beta Immune Cells in Mucosal Immunity, Tolerance and Cancer
Hilde Cheroutre,
La Jolla Institute for Allergy and Immunology, USA
A Give-and-Take Relation between TGF-beta and the Gut Environment Drives the CD4 CTL Fate
A Give-and-Take Relation between TGF-beta and the Gut Environment Drives the CD4 CTL Fate
Yingzi Cong,
University of Texas Medical Branch, USA
TGF-beta Regulation of Host-Microbiota Interaction at Mucosal Surface
TGF-beta Regulation of Host-Microbiota Interaction at Mucosal Surface
Mark A. Travis,
University of Manchester, UK
Short Talk: Human Blood Monocyte and Intestinal Macrophage Populations Regulate TGF-beta Activity via Expression of the Integrin Alphav beta8
Short Talk: Human Blood Monocyte and Intestinal Macrophage Populations Regulate TGF-beta Activity via Expression of the Integrin Alphav beta8
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
TGF-ß in Inflammatory Diseases: Mechanisms and Immunotherapy
Meeting has ended...abstracts no longer viewable online.
Danielle Smyth,
University of Glasgow, UK
Short Talk: Identification of a Novel and Potent Mimic of TGF-beta Secreted by the Helminth Parasite Heligmosomoides Polygyrus
Short Talk: Identification of a Novel and Potent Mimic of TGF-beta Secreted by the Helminth Parasite Heligmosomoides Polygyrus
*
Megan K. Levings,
University of British Columbia, Canada
Mechanisms of Suppression by Human Regulatory T Cells
Mechanisms of Suppression by Human Regulatory T Cells
Lucienne Chatenoud,
INSERM U1151, Hôpital Necker-Enfants Malades, France
CD3-Antibody, TGF-ß and Type I Diabetes
CD3-Antibody, TGF-ß and Type I Diabetes
Coffee Break
Lingyun Sun,
Nanjing University Medical School, China
TGF-beta in Mesenchymal Stem Cell-Mediated Immnoregulation in Autoimmune Diseases
TGF-beta in Mesenchymal Stem Cell-Mediated Immnoregulation in Autoimmune Diseases
Daniel H. Kaplan,
University of Pittsburgh, USA
Stromal Cells Control Epithelial Residence of Dendritic Cells and Memory T Cells through Regulated Activation of Latent TGF-b
Stromal Cells Control Epithelial Residence of Dendritic Cells and Memory T Cells through Regulated Activation of Latent TGF-b
Vlad Senatorov,
University of California, Berkeley, USA
Short Talk: Neuro-Inflammatory Astrocytic TGF-beta Signaling after Blood-Brain Barrier Disruption: A Novel Mechanism Underlying Age-Related Seizure Vulnerability and Cognitive Decline
Short Talk: Neuro-Inflammatory Astrocytic TGF-beta Signaling after Blood-Brain Barrier Disruption: A Novel Mechanism Underlying Age-Related Seizure Vulnerability and Cognitive Decline
14:30—16:30
Workshop 2: TGF-ß in Inflammatory Diseases and Cancer
*
Joanne E. Konkel,
University of Manchester, UK
*
Lingyun Sun,
Nanjing University Medical School, China
Gabriela Dveksler,
Uniformed Services University of the Health Sciences, USA
Proteins Secreted from the Human Placenta Activate Latent TGF-b and Demonstrate Therapeutic Potential
Proteins Secreted from the Human Placenta Activate Latent TGF-b and Demonstrate Therapeutic Potential
Piotr Jachimczak,
RealTVac, Germany
A Novel Strategy to Treat Advanced, Late-Stage Tumors with Real-Time Tumor Vaccination - RealTVac®
A Novel Strategy to Treat Advanced, Late-Stage Tumors with Real-Time Tumor Vaccination - RealTVac®
James Gulley,
NCI, National Institutes of Health, USA
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-beta, in Advanced Solid Tumors
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-beta, in Advanced Solid Tumors
David F. Vincent,
CRUK - Beatson Institute for Cancer Research, UK
Genetic Mouse Models of Bowel Cancer Reveal the Role of TGF-beta Signaling in Intestinal Stem Cell Homeostasis and Cancer
Genetic Mouse Models of Bowel Cancer Reveal the Role of TGF-beta Signaling in Intestinal Stem Cell Homeostasis and Cancer
Shaopeng Yuan,
Rockefeller University, USA
TGF-beta Responsive Tumor Stem Cell Development and Drug Resistance in Squamous Cell Carcinoma
TGF-beta Responsive Tumor Stem Cell Development and Drug Resistance in Squamous Cell Carcinoma
17:00—18:45
TGF-ß in Cancer: Signaling in Cancer Cells and Immunotherapy for Cancer
Meeting has ended...abstracts no longer viewable online.
*
Peter ten Dijke,
Leiden University Medical Center, Netherlands
Lalage M. Wakefield,
NCI, National Institutes of Health, USA
Anti-TGF-beta Antibody Therapy: Lessons from Pre-Clinical Cancer Models
Anti-TGF-beta Antibody Therapy: Lessons from Pre-Clinical Cancer Models
Karim A. Benhadji,
Eli Lilly and Company, USA
Clinical Development of TGF-b Receptor Inhibitors in Cancer
Clinical Development of TGF-b Receptor Inhibitors in Cancer
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
